SURG-01 IS UNRESECTED GLIOBLASTOMA TRULY UNRESECTABLE? AN ANALYSIS OF BASAL MRI'S OF PATIENTS WITH UNRESECTED GLIOBLASTOMA INCLUDED IN THE GENOM009 TRIAL AND THE VARIABILITY OF SURGICAL APPROACHES

Схожие документы

• P17.04 RANO CRITERIA APPLIED TO A PHASE II RANDOMIZED, MULTICENTER TRIAL COMPARING TEMOZOLOMIDE (TMZ) VS TMZ-PLUS-BEVACIZUMAB (BEV) BEFORE STANDARD TREATMENT IN UNRESECTABLE GLIOBLASTOMA (GBM) PATIENTS (P).GENOM 009 STUDY BY THE GEINO GROUP
  по: Balaña, C., et al.
  Опубликовано: (2014)
• Pyrosequencing versus methylation-specific PCR for assessment of MGMT methylation in tumor and blood samples of glioblastoma patients
  по: Estival, Anna, et al.
  Опубликовано: (2019)
• ATCT-05 OBJECTIVE RESPONSE (OR) TO NEOADJUVANT TREATMENT IN GLIOBLASTOMA AND ITS IMPACT ON OVERALL SURVIVAL (OS). A META-ANALYSIS OF NEOADJUVANT TRIALS OF THE SPANISH GROUP FOR RESEARCH IN NEUROONCOLOGY (GEINO)
  по: Balana, Carmen, et al.
  Опубликовано: (2015)
• ACTR-48. AN APPRAISAL OF THE IMPACT ON SURVIVAL OF NEOADJUVANT TREATMENTS DELAYING RADIOTHERAPY IN ‘ONLY-BIOPSIED GLIOBLASTOMA’ TRIALS CONDUCTED BY THE GEINO GROUP COMPARED TO PATIENTS TREATED WITH THE STUPP’S REGIME. EXPERIENCE OF THE GEINO AND THE GLIOCAT GROUP
  по: Balana, Carme, et al.
  Опубликовано: (2017)
• Geometrical Measures Obtained from Pretreatment Postcontrast T1 Weighted MRIs Predict Survival Benefits from Bevacizumab in Glioblastoma Patients.
  по: David Molina, et al.
  Опубликовано: (2016-01-01)